Abliva is a Swedish drug development company based in Lund. It is a public company focused on developing treatments for a rare group of largely genetic disorders known as primary mitochondrial diseases. Its lead product KL 1333 is intended for the treatment of MELAS and MELAS-like syndromes. The product is in clinical development.
YEAR OF INVESTMENT